Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Pulmonary Edema Companies

Pulmonary Edema companies lead the charge in respiratory care, specializing in research and solutions for this life-threatening condition. Committed to advancing diagnostics and treatments, these organizations play a pivotal role in improving outcomes for individuals facing pulmonary edema.

Pulmonary Edema Market

Latest Pulmonary Edema Companies Updates:

April 2023: ResMed acquired Propeller Health, a leader in digital health solutions for respiratory diseases, including pulmonary edema. This move strengthens ResMed's portfolio in remote patient monitoring and data-driven care management.

March 2023: AstraZeneca entered into a collaboration with BioNTech to develop novel immune-oncology therapies for various disease indications, including pulmonary edema associated with lung cancer.

November 2023: Novartis received FDA approval for Entresto (sacubitril/valsartan) for the treatment of heart failure with preserved ejection fraction (HFpEF), a condition that can lead to

pulmonary edema. This approval expands the potential patient base for Entresto.

September 2023: Verve Therapeutics announced the first patient dosed in a Phase 1b clinical trial for VERVE-101, a potential gene therapy for the treatment of pulmonary edema associated with pulmonary arterial hypertension.

List of Pulmonary Edema Key companies in the market:

Pfizer Inc. (U.S.)

ARGON MEDICAL (U.S.)

Edwards Lifesciences Corporation (U.S.)

BD (U.S.)

Alcaliber S.A. (Spain)

Lupin Pharmaceuticals, Inc. (India)

Vitaltec Corporation (China)

Medtronic (U.S.)

Koninklijke Philips N.V. (The Netherlands)

Siemens Healthcare GmbH (Germany)

Pulmonary Edema Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.